BioMarin Pharmaceutical Inc (BMRN) stock
BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3091% above fair value
$57.23+0.53 (+0.93%)
Close on Nov 13, 2026Market cap $11.08BP/E 150.6Yield –
BioMarin Pharmaceutical statistics
105 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Feb 22, 2027 (estimated, after the close)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Jun 30, 2026
- Share price as of
- Nov 13, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 14.08
- 2.22
- P/OCF Ratio
- 12.93
- 12.99
Enterprise valuationIndustry
- EV / Sales
- 4.22
- 2.57
- EV / EBIT
- 96.41
- 19.31
- EV / FCF
- 19.49
- 22.27
Share statisticsIndustry
- Shares Change (YoY)
- -0.56%
- 10.8%
- Shares Change (QoQ)
- 0.14%
- 0.50%
- Float
- 193M
- 49M
- Shares Held by Insiders
- 0.52%
- 11.7%
- Shares Held by Institutions
- 101.1%
- 56.4%
Short sellingIndustry
- Short Interest
- 14M
- –
- Short Interest Change
- 17.2%
- -0.80%
- Short % of Float
- 7.33%
- 9.01%
- Short % of Shares Outstanding
- 7.30%
- 6.30%
- Days to Cover
- 5.77
- 5.15
Stock price statisticsIndustry
- 52-Week High
- $70.98
- –
- 52-Week Low
- $49.26
- –
- 20-Day Moving Average
- $56.55
- –
- 50-Day Moving Average
- $58.86
- –
- 200-Day Moving Average
- $58.46
- –
- Average True Range (14)
- $1.82
- –
- Price Change (1 Week)
- 2.14%
- -1.15%
- Price Change (1 Month)
- 2.11%
- -4.87%
- Price Change (3 Months)
- -14.1%
- -21.0%
- Price Change (6 Months)
- 10.5%
- -20.6%
- Price Change (YTD)
- -3.70%
- -23.6%
- Price Change (1 Year)
- 3.45%
- -22.4%
- Price Change (3 Years)
- -32.6%
- -29.5%
- Price Change (5 Years)
- -30.0%
- -77.9%
- Price Change (10 Years)
- -38.4%
- -65.4%
- Average Volume (10 Days)
- 2M
- –
- Average Volume (20 Days)
- 2M
- –
- Average Volume (90 Days)
- 2M
- –
- Relative Volume
- 0.68
- 0.70
- Relative Strength Index (14)
- 50.1
- 43.4
- Volatility (1 Year)
- 35.3%
- 80.1%
- Beta (5 Years)
- 0.59
- 1.07
MarginsIndustry
- Pretax Margin
- 4.38%
- -11.6%
- EBITDA Margin
- 8.87%
- -27.7%
- FCF Margin
- 21.7%
- -9.56%
Returns on capitalIndustry
- Return on Equity (ROE)
- 1.18%
- -49.9%
- Return on Assets (ROA)
- 0.76%
- -40.6%
- Return on Invested Capital (ROIC)
- 1.05%
- -32.9%
- Return on Capital Employed (ROCE)
- 1.48%
- -37.9%
Financial positionIndustry
- Current Ratio
- 2.39
- 3.30
- Quick Ratio
- 1.16
- 2.39
- Debt / Equity
- 0.66
- 0.49
- Debt / EBITDA
- 13.85
- 3.15
- Debt / FCF
- 5.67
- 4.65
- Net Debt / EBITDA
- 10.96
- 1.97
- Interest Coverage
- 1.97
- -6.35
GrowthIndustry
- Revenue Growth (YoY)
- 11.2%
- 6.82%
- Net Income Growth (YoY)
- -88.9%
- -14.4%
- EPS Growth (YoY)
- -88.7%
- -12.3%
- FCF Growth (YoY)
- 6.23%
- 6.85%
- Revenue Growth (3Y CAGR)
- 15.4%
- 2.25%
- Revenue Growth (5Y CAGR)
- 11.6%
- 6.41%
- EPS Growth (3Y CAGR)
- 33.9%
- 1.30%
- EPS Growth (5Y CAGR)
- -16.7%
- 3.78%
EfficiencyIndustry
- Asset Turnover
- 0.36
- 0.40
- Inventory Turnover
- 0.52
- 2.73
- Revenue Per Employee
- $1.06M
- $429.29K
- Profits Per Employee
- $22.66K
- -$689.41K
- Employee Count
- 3,221
- 74
- WACC
- 6.75%
- 10.2%
Income statement (TTM)Industry
- Pretax Income
- $149.11M
- -$12.95M
Balance sheetIndustry
- Net Cash (Debt)
- -$3.31B
- $17.76M
- Net Cash Per Share
- -$17.11
- $0.80
- Equity (Book Value)
- $6.32B
- $53.89M
- Book Value Per Share
- $32.66
- $1.50
- Tangible Book Value
- $786.58M
- $27.13M
- Working Capital
- $2.31B
- $79.99M
Cash flow (TTM)Industry
- Capital Expenditures
- -$118.91M
- -$1.00M
- FCF Per Share
- $3.81
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- 0.66%
- -21.8%
- FCF Yield
- 6.66%
- -9.44%
Taxes and interestIndustry
- Interest Expense
- $75.66M
- $2.90M
- Income Tax
- $76.14M
- $73.00K
- Effective Tax Rate
- 51.1%
- 20.9%
Scores and fair valueIndustry
- Graham Number
- $16.71
- $19.34
- Graham Upside
- -70.8%
- -46.6%
- Altman Z-Score
- 1.84
- 0.23
- Piotroski F-Score
- 4
- 4
- Beneish M-Score
- -2.82
- -2.63
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | BMRN | S&P 500 | Difference | BMRN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +5.2% | -3.0% | +8.3 pts | ||
| 3 months | -16.5% | -2.8% | −13.7 pts | ||
| Year to date | -3.7% | +11.5% | −15.2 pts | ||
| 1 year | +5.6% | +13.5% | −7.9 pts | ||
| 3 years | -31.4% | +77.7% | −109.1 pts | -11.8% | +21.1% |
| 5 years | -30.0% | +72.6% | −102.6 pts | -6.9% | +11.5% |
| 10 years | -37.4% | +308.2% | −345.6 pts | -4.6% | +15.1% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
14M BMRN shares were sold short on Oct 30, 2026, up 17.2% from the previous report, or 7.33% of the shares available to trade. At recent volumes it would take 5.8 days to buy them back. Over the last 20 sessions, 61.3% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 14,122,815 | +17.2% | 2,447,467 | 5.8 |
| Oct 15, 2026 | 12,050,657 | +4.6% | 2,458,966 | 4.9 |
| Sep 30, 2026 | 11,522,835 | +14.4% | 2,090,642 | 5.5 |
| Sep 15, 2026 | 10,075,655 | +2.0% | 1,822,750 | 5.5 |
| Aug 31, 2026 | 9,877,553 | -3.2% | 1,713,708 | 5.8 |
| Aug 14, 2026 | 10,202,950 | -18.4% | 2,767,411 | 3.7 |
| Jul 31, 2026 | 12,504,131 | -12.7% | 1,684,263 | 7.4 |
| Jul 15, 2026 | 14,315,984 | +2.9% | 1,409,304 | 10.2 |
| Jun 30, 2026 | 13,908,847 | +11.1% | 2,301,848 | 6.0 |
| Jun 15, 2026 | 12,516,448 | +7.9% | 2,066,601 | 6.1 |
| May 29, 2026 | 11,605,279 | +2.2% | 2,921,395 | 4.0 |
| May 15, 2026 | 11,359,229 | +5.2% | 2,096,087 | 5.4 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?